| Product Name | Tepotinib - API |
| Product Code | DA-T356-a |
| Chemical name | Tepotinib |
| Synonyms | A257; EMD 1214063; MSC 2156119; MSC'119; 3-{1-[(3-{5-[(1-Methylpiperidin-4-yl)methoxy]pyrimidin2-yl}phenyl)methyl]-6-oxo-1,6-dihydropyridazin3-yl}benzonitrile; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; 3-[1,6-Dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]benzonitrile; |
| Impurity | NA |
| CAS Number | 1100598-32-0 |
| Alternate CAS # | NA |
| Molecular form | C29H28N6O2 |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 492.58 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | impurities,metabolites,pharmaceutical standards,intermediates,Fine Chemicals |
| Boiling Point | NA |
| Applications | Tepotinib is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.Tepotinib, sold under the brand name Tepmetko, is a medication used for the treatment of adults with non-small cell lung cancer (NSCLC). |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
